Check Claims Before You Publish

Visual author review — Douglas W. Selinger

Visualization first: citation footprint across Selinger's most-cited papers (raw citation counts from bibliographic records reported by indexing sources).

What the raw metrics and paper content indicate

• Focused domain impact: Selinger's highest-impact empirical contributions are genome-scale bacterial transcriptomics (RNA half-lives and subgenic expression arrays) that provided foundational datasets later reused by others for RNA decay, operon structure, and supercoiling studies Genome Research 2003 RNA half-life
• Methodological contribution: Early microarray platform design at 30-bp resolution advanced subgenic mapping capabilities and influenced later genomics-methods papers Nature Biotechnology 2000 microarray
• Breadth vs. depth: Later and coauthored works expand into high-throughput profiling, screens, and translational data warehouses (Novartis-associated projects), indicating movement from academic bacterial genomics toward applied/translational computational-biology problems (mechanism-of-action screens, compound profiling) SLAS DISCOVERY 2012 MD-PV metric

Strengths (evidence-based)

• Produces reproducible, widely-cited empirical datasets (two papers >300 citations each) that other researchers reuse as primary resources Genome Research 2003 RNA half-life
• Method and metrics orientation: coauthorship on methodological and metric papers (microarrays, MD-PV) suggests strength in designing quantitative analyses for high-dimensional biological data SLAS DISCOVERY 2012 MD-PV metric

Limitations, blindspots, and cautionary points

• Domain concentration: major impact is concentrated in bacterial transcriptomics and microarray-era methods; fewer widely-cited contributions in mammalian molecular mechanisms or clinical translational endpoints, which constrains breadth of biological claims.
• Authorship roles and team science: many later papers are collaborative with industry groups (Novartis, Genomics Institute of Novartis Research Foundation); interpretation of contribution should be cautious because middle/consortium authorship may reflect methodological support rather than leading hypothesis-driven biology.
• Method age & technology evolution: several foundational works used microarrays (2000–2003); microarrays have known biases (probe hybridization, limited dynamic range) and have largely been superseded by RNA-seq—while the datasets remain valuable, their technical limitations must be considered when reusing them.
• Reproducibility & scope: top datasets are condition-specific (strain, growth condition); conclusions about general principles of RNA decay require replication across strains/conditions and modern sequencing platforms.

Concrete, evidence-supported takeaways

1. Selinger produced at least two empirically influential datasets (2000, 2003) that are strong contributions to bacterial transcriptomics and methods development Genome Research 2003 RNA half-life Nature Biotechnology 2000 microarray
2. When evaluating claims built on these datasets, users must account for platform-specific biases (microarray vs RNA-seq), experimental condition dependence, and the collaborative/industrial contexts of later translational work.

What additional data would change this evaluation?

• Availability of modern RNA-seq reanalysis of Selinger's samples, or replication under multiple conditions/strains, would strengthen claims of generality about bacterial RNA decay.
• Clear author contribution statements (who led experimental design vs computational analysis) for later Novartis/industry papers would allow more precise attribution of intellectual leadership.

Selected references (anchor to source evidence)

• Genome Research 2003 RNA half-life
• Nature Biotechnology 2000 microarray
• Trends Biotech 2003 perspective
• SLAS DISCOVERY 2012 MD-PV metric

Suggested follow-ups (one-click actions)